← Back to Search
Bcr-Abl Variants: Biological And Clinical Aspects.
A. Advani, A. Pendergast
Published 2002 · Medicine, Biology
Download PDFAnalyze on Scholarcy
Bcr-Abl is an oncogene that arises from fusion of the Bcr gene with the c-Abl proto-oncogene. Three different Bcr-Abl variants can be formed, depending on the amount of Bcr gene included: p185, p210, and p230. The three variants are associated with distinct types of human leukemias. Examination of the signaling pathways differentially regulated by the Bcr-Abl proteins will help us gain better insight into Bcr-Abl mediated leukemogenesis.
This paper references
Regulation of the oncogenic activity of BCR-ABL by a tightly bound substrate protein RIN1.
D. Afar (1997)
Molecular analysis of Philadelphia positive essential thrombocythemia.
P. Martiat (1989)
Cytogenetic studies of haemopoietic colonies from patients with an initial diagnosis of acute lymphoblastic leukaemia
D. Kalousek (1988)
BCR/ABL inhibition by an escort/phosphatase fusion protein.
Y. M. Lim (2000)
Sequence and analysis of the human ABL gene, the BCR gene, and regions involved in the Philadelphia chromosomal translocation.
S. Chissoe (1995)
p62dok: A Constitutively Tyrosine-Phosphorylated, GAP-Associated Protein in Chronic Myelogenous Leukemia Progenitor Cells
N. Carpino (1997)
Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group.
A. Delannoy (1997)
Donor lymphocyte infusions
S. Giralt (1996)
OPTIONS FOR THERAPY IN CHRONIC MYELOID LEUKAEMIA
A. Spencer (1995)
Difference of cell lineage expression of haematopoietic progenitor cells in Philadelphia‐positive acute lymphoblastic leukaemia and chronic myelogenous leukaemia
K. Kitano (1988)
In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome.
J. Mclaughlin (1987)
The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia.
H. Ahuja (1991)
P210 and P190BCR/ABL Induce the Tyrosine Phosphorylation and DNA Binding Activity of Multiple Specific STAT Family Members*
R. Ilaria (1996)
Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor.
H. Kantarjian (1992)
The SH2 domain of ABL is not required for factor-independent growth induced by BCR-ABL in a murine myeloid cell line.
T. Oda (1995)
p53 in chronic myelogenous leukemia in acute phase.
E. Feinstein (1991)
The P190, P210, and P230 Forms of the BCR/ABL Oncogene Induce a Similar Chronic Myeloid Leukemia–like Syndrome in Mice but Have Different Lymphoid Leukemogenic Activity
Shaoguang Li (1999)
The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells
D. Cortez (1997)
Differences in tyrosine phosphorylated proteins between cells expressing P210bcr/abl and P190bcr/abl.
J. Nishimura (1992)
Chronic myelogenous leukemia: a review.
J. Cortes (1996)
Chronic myelogenous leukemia: update on biology and treatment.
S. Faderl (1999)
axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase.
J. O’Bryan (1991)
A requirement for NF-κB activation in Bcr–Abl-mediated transformation
J. Y. Reuther (1998)
Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines.
E. Weisberg (2000)
Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high‐dose cytosine arabinoside
H. Kantarjian (1988)
Definition of the accelerated phase of chronic myelogenous leukemia.
H. Kantarjian (1988)
Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.
D. G. Peters (2001)
Cytogenetic response to alpha-interferon is predicted in early chronic phase chronic myeloid leukemia by M-bcr breakpoint location.
S. Elliott (1995)
The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.
S. Roumiantsev (2001)
Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients.
J. Radich (1995)
First intron and M-bcr breakpoints are restricted to the lymphoid lineage in Philadelphia positive acute lymphoblastic leukemia.
J. M. Craig (1990)
The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype.
J. Melo (1996)
Chronic myeloid leukemia
J. Goldman (1997)
Transformation of hematopoietic cells by BCR/ABL requires activation of a PI‐3k/Akt‐dependent pathway
T. Skorski (1997)
Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
J. Goldman (2001)
Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon.
T. Lion (1995)
The significance of cytogenetic findings of erythroid colonies derived from a Ph+ ALL patient: fundamental differences between Ph+ ALL and blastic phase CML.
R. Abe (1985)
Altered transcription of the c-abl oncogene in K-562 and other chronic myelogenous leukemia cells.
S. Collins (1984)
Abr and Bcr are multifunctional regulators of the Rho GTP-binding protein family.
T. Chuang (1995)
A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining
J. Rowley (1973)
Biology of BCR-ABL.
R. Chopra (1999)
The biology of chronic myeloid leukemia.
S. Faderl (1999)
Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression.
A. Gaiger (1995)
Comparative biochemical and cytogenetic studies of childhood acute lymphoblastic leukemia with the Philadelphia chromosome and other 22q 11 variants
L. Dow (1989)
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
B. Druker (1996)
Characteristics of accelerated disease in chronic myelogenous leukemia
H. Kantarjian (1988)
BCR – ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner
N. Cambier (1998)
Lineage switch in Philadelphia chromosome‐ positive acute lymphoblastic leukemia
David A. Reardon (1994)
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.
G. Q. Daley (1990)
Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.
E. Buchdunger (1996)
rac, a novel ras-related family of proteins that are botulinum toxin substrates.
J. Didsbury (1989)
Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.
T. G. Lugo (1990)
Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.
F. X. Mahon (2000)
Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction)
F. Pane (1996)
The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation.
A. B. Raitano (1995)
A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia positive acute lymphoblastic leukaemia
L. C. Chan (1987)
Variable Philadelphia breakpoints and potential lineage restriction of bcr rearrangement in acute lymphoblastic leukemia
L. Secker-Walker (1988)
The cytogenetic scenario of chronic myeloid leukemia.
F. Mitelman (1993)
Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis.
D. Cortez (1995)
Clonal nature of chronic neutrophilic leukemia [letter] [see comments]
Y. Kwong (1993)
Chronic myelogenous leukemia.
M. Mauro (1994)
5 Therapy and prognostic factors in adult acute lymphoblastic leukaemia
D. Hoelzer (1994)
Abl tyrosine kinase in signal transduction and cell-cycle regulation.
J. Wang (1993)
Heterogeneity in lineage derivation of Philadelphia-positive acute lymphoblastic leukemia expressing p190BCR-ABL or p210BCR-ABL: determination by analysis of individual colonies with the polymerase chain reaction.
Z. Estrov (1993)
Expression of Constitutively Active Raf-1 in the Mitochondria Restores Antiapoptotic and Leukemogenic Potential of a Transformation-deficient BCR/ABL Mutant
P. Salomoni (1998)
Effect of Bcr sequences on the cellular function of the Bcr-Abl oncoprotein
John R McWhirter (1997)
BCR/ABL rearrangement and leukemia phenotype
G. Saglio (1999)
Chronic myeloid leukemia.
C. Sawyers (1999)
Ph-positive chronic myeloid leukemia mimicking essential thrombocythemia and terminating into megakaryoblastic blast crisis: report of two cases with molecular studies.
F. Cervantes (1993)
A CASE OF SPLENOMEGALY WITH POLYMORPHONUCLEAR NEUTROPHIL HYPERLEUKOCYTOSIS
E. L. Tuohy (1920)
Clinical impact of breakpoint position within M-bcr in chronic myeloid leukemia.
T. Fioretos (1993)
Abnormal integrin-mediated regulation of chronic myelogenous leukemia CD34+ cell proliferation: BCR/ABL up-regulates the cyclin-dependent kinase inhibitor, p27Kip, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity.
Y. Jiang (2000)
BCR-ABL: an anti-apoptosis gene in chronic myelogenous leukemia.
T. Cotter (1995)
P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia?
J. Melo (1994)
Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1.
K. Okuda (1994)
Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases.
R. C. Quackenbush (2000)
Mouse disabled (mDab1): a Src binding protein implicated in neuronal development
B. Howell (1997)
BCR-ABL Maintains Resistance of Chronic Myelogenous Leukemia Cells to Apoptotic Cell Death
A. J. McGahon (1994)
p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.
F. van Rhee (1996)
Analysis of the clinical relevance of the breakpoint location within M-BCR and the type of chimeric mRNA in chronic myelogenous leukemia.
C. Rozman (1995)
Novel therapies for chronic myelogenous leukemia.
B. Jahagirdar (2001)
Chromosome abnormalities in malignant hematologic diseases.
J. Rowley (1982)
Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells.
C. A. Evans (1993)
Inversion of chromosome 16 and bone marrow eosinophilia in a myelomonocytic transformation of chronic myeloid leukemia.
N. Asou (1992)
Signal transduction by wild-type and leukemogenic Abl proteins.
A. B. Raitano (1997)
Interactions of p62 dok with p210 bcr-abl and Bcr-Abl-associated Proteins*
A. Bhat (1998)
A cytoplasmic inhibitor of the JNK signal transduction pathway.
M Dickens (1997)
Karyotypic findings as an independent prognostic marker in chronic myeloid leukaemia blast crisis.
G. Nanjangud (1994)
Growth factor independence and BCR/ABL transformation: promise and pitfalls of murine model systems and assays
S Ghaffari (1999)
Chronic myeloid leukemia from basics to bedside
S. Thijsen (1999)
Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro.
M. Gishizky (1992)
Consistent amounts of acute leukemia-associated P190BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis.
G. Saglio (1996)
Signaling by ABL oncogenes through cyclin D1.
D. Afar (1995)
Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients.
H. Kantarjian (1987)
A possible correlation between the type of bcr-abl hybrid messenger RNA and platelet count in Philadelphia-positive chronic myelogenous leukemia [see comments]
K. Inokuchi (1991)
Reduced oncogenicity of p190 Bcr/Abl F-actin-binding domain mutants.
N. Heisterkamp (2000)
Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway.
Z. Dai (1998)
Identification of the Abl- and rasGAP-Associated 62 kDa Protein as a Docking Protein, Dok
Y. Yamanashi (1997)
Mutations of the ras protooncogenes in chronic myelogenous leukemia: a high frequency of ras mutations in bcr/abl rearrangement-negative chronic myelogenous leukemia
Pc Cogswell (1989)
Outcome of Philadelphia Chromosome-Positive Adult Acute Lymphoblastic Leukemia
S. Faderl (2000)
Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
K. Shuai (1996)
Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis.
P. M. Derderian (1993)
Changes in oncogene expression implicated in evolution of chronic granulocytic leukemia from its chronic phase to acceleration.
Z. Beck (1998)
Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed Myeloid Cells*
A. Bhat (1997)
Implicating the bcr/abl gene in the pathogenesis of Philadelphia chromosome-positive human leukemia.
G. Q. Daley (1991)
Analysis of molecular breakpoint and m‐RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival
P. Shepherd (1995)
The SH2 domain of bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype.
X. Zhang (2001)
p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines.
K. Okuda (1996)
BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein
A. Pendergast (1993)
Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.
T. Schindler (2000)
Entire ABL gene is joined with 5'-BCR in some patients with Philadelphia-positive leukemia.
C. Morris (1991)
Mapping of breakpoints, and relationship to BCR-ABL RNA expression, in Philadelphia-chromosome-positive chronic myeloid leukaemia patients with a breakpoint around exon 14 (b3) of the BCR gene.
K. Mills (1991)
The role of myc in transformation by BCR-ABL.
C. Sawyers (1993)
Genetic approaches to defining signaling by the CML-associated tyrosine kinase BCR-ABL.
D. Afar (1994)
Differential complementation of Bcr-Abl point mutants with c-Myc.
D. Afar (1994)
BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner
A. Pendergast (1991)
Dominant negative MYC blocks transformation by ABL oncogenes
C. Sawyers (1992)
Absence of the human retinoblastoma gene product in the megakaryoblastic crisis of chronic myelogenous leukemia.
M. Towatari (1991)
Differentiation patterns in the blastic phase of chronic myeloid leukemia.
J. Griffin (1983)
Philadelphia chromosome-positive leukaemia: the translocated genes and their gene products.
P. Allen (1992)
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
M. E. Gorre (2001)
Preliminary results of a randomized study of adjuvant radiation therapy in resectable adult retroperitoneal soft tissue sarcomas.
T. Kinsella (1988)
Molecular consequences of the BCR-ABL translocation in chronic myelogenous leukemia.
C. Sawyers (1993)
Chronic myelogenous leukemia: a concise update.
H. Kantarjian (1993)
Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene
C. Sawyers (1995)
The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors
A. Ridley (1992)
Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia.
H. Kantarjian (1991)
A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia
R. Kurzrock (1987)
Regulation of the c-jun gene in p210 BCR-ABL transformed cells corresponds with activity of JNK, the c-jun N-terminal kinase.
G. Burgess (1998)
BCR/ABL-induced Leukemogenesis Causes Phosphorylation of Hef1 and Its Association with Crkl*
R. de Jong (1997)
Tyrosine Phosphorylation of Tub and Its Association with Src Homology 2 Domain-containing Proteins Implicate Tub in Intracellular Signaling by Insulin*
R. Kapeller (1999)
Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells.
T. Skorski (1995)
Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells.
J. Mclaughlin (1989)
BCR-ABL gene variants.
J. Melo (1997)
Allogeneic bone marrow transplantation for chronic myeloid leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation (EBMT).
A. Gratwohl (1996)
Successful alpha‐2b‐interferon therapy for chronic neutrophilic leukemia
S. Meyer (1993)
Transforming genes in chronic myelogenous leukemia.
E. Liu (1988)
This paper is referenced by
Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products
K. S. Siveen (2018)
Molecular biology of prostate cancer
M. Karayi (2004)
Frequency of p190 and p210 BCR-ABL rearrangements and survival in Brazilian adult patients with acute lymphoblastic leukemia
Ilana de França Azevedo (2014)
Attomolar electrochemical detection of the BCR/ABL fusion gene based on an amplifying self-signal metal nanoparticle-conducting polymer hybrid composite.
Karen Yasmim Pereira dos Santos Avelino (2016)
Abstract. Smad4 is a critical regulator of transforming growth factor (TGF)-β signaling and is defective in numerous human cancers. In total, 30% of pancreatic cancers harbor a homozy-
Onica Legendre (2014)
Net1 and Myeov: computationally identified mediators of gastric cancer
J. Leyden (2006)
Arg/Abl2 promotes invasion and attenuates proliferation of breast cancer in vivo
H. Gil-Henn (2013)
THE ROLE OF MED 12 IN TUMORIGENESIS
K. Kämpjärvi (2016)
Diagnostic value of detecting fusion proteins derived from chromosome translocations in acute leukaemia.
F. Lococo (2003)
How do Abl family kinases regulate cell shape and movement?
S. E. Hernández (2004)
The mechanism of CD24-mediated apoptosis in bone marrow-derived early B-cells.
D. Ayre (2014)
Resveratrol induces human K562 cell apoptosis, erythroid differentiation, and autophagy
Hui-Wen Yan (2014)
NET1-mediated RhoA activation facilitates lysophosphatidic acid-induced cell migration and invasion in gastric cancer
D. Murray (2008)
Chronic Myeloid Leukemia, BCR-ABL1 Positive
R. Wang (2018)
Induction of apoptosis by curcumin: mediation by glutathione S-transferase P1-1 inhibition.
A. Duvoix (2003)
Ph-positive leukemias in the era of modern cytogenetics, molecular biology, tyrosine kinase inhibitors and hematopoietic stem cell transplantation
Nikolay Mamaev (2010)
Pharmacogenomics and Laboratory Medicine
Jianbo Song (2016)
Deficiency of the adaptor SLP-65 in pre-B-cell acute lymphoblastic leukaemia
H. Jumaa (2003)
Molecular Diagnostics in Neoplastic Hematopathology
D. Arber (2004)
The role of PI3K in Ephrin-A1 induced cell retraction
Daniel James Fero (2008)
The structural basis for cancer treatment decisions
R. Nussinov (2014)
Role of the drug transporters in the multidrug resistance affecting bosutinib treatment
P. Perini (2011)
Mouse Models of Human Blood Cancers
S. Li (2008)
Molecular Pathology of Hematological Malignancies
A. Killeen (2004)
Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia-retrospective study and review of literature.
Y. Keung (2004)
Imatinib induces mitochondria‐dependent apoptosis of the Bcr‐Abl‐positive K562 cell line and its differentiation toward the erythroid lineage 1
A. Jacquel (2003)
Regulation of the Apoptosome in Cancer
Jiyeon Kim (2012)
Modeling Human Philadelphia Chromosome-Positive Leukemia in Mice
S. Li (2008)
Investigating allosteric regulation of ABL and BCR-ABL kinases: Implications for small molecule inhibitors
Shoghag B. Panjarian (2012)
Identification of T-cell epitopes for cancer immunotherapy
J. H. Kessler (2007)
J. Wu (2004)
Using Bcr-Abl to examine mechanisms by which abl kinase regulates morphogenesis in Drosophila.
Traci Stevens (2008)See more